Fatigue is the most common, distressing, and persistent symptom in patients with cancer, 1 present in 60-96% of patients with various malignancies. Patients identified fatigue as being more important to treat than pain. 1 Fatigue impacts significantly on quality of life (QOL), leads to restrictions in activities, and is particularly severe during chemotherapy or radiotherapy.
Only one study has focused on fatigue in patients with acute myeloid leukemia (AML). 2 Among 37 patients ages 16-70, fatigue was the most common symptom and occurred in the majority of patients at baseline. At the completion of induction therapy, and up to 1 year later, fatigue scores improved by about 50%. Fatigue correlated positively with loss of appetite and negatively with emotional function. 2 AML is primarily a disease of older adults; more than 60% of patients are over age 60 at diagnosis. There are important differences in the etiology, response to chemotherapy, and prognosis of AML between older and younger adults. As such, prevalence, severity and etiology of fatigue may be different in this population. Understanding these issues is crucial to designing interventions to minimize fatigue.
We studied patients with age 60 or older with AML to characterize the prevalence and severity of fatigue, to examine correlations between fatigue and both QOL and functional status, and to examine correlations between fatigue and potential sociodemographic and clinical variables.
Consecutive, newly diagnosed, English-speaking patients were approached before starting chemotherapy. Follow-up visits were conducted at 1 month, 4 months, and 6 months. Patients with another active malignancy, life expectancy of less than 1 month, or significant cognitive impairment were excluded. Patients were recruited primarily from the Princess Margaret Hospital (PMH), an academic tertiary care cancer center and the major referral center for most patients with acute leukemia in the Greater Toronto Area (catchment area of 4.5 million). All patients provided written, informed consent. The study was approved by the PMH Research Ethics Board.
Treatment was stratified into intensive chemotherapy (IC) or non-IC. IC consisted of one or two courses of induction chemotherapy (3 days of daunorubicin 60 mg/m 2 /day and 7 days of cytosine arabinosine (Ara-C) 100 mg/m 2 /day). First consolidation consisted of the same regimen as induction. Most patients received a second consolidation with mitoxantrone (10 mg/m 2 /day) and etoposide (100 mg/m 2 /day) each for 5 days. Non-IC included investigational agents (temozolomide and decitabine) or best supportive care.
Fatigue was measured with three separate instruments. The primary measure was the Functional Assessment of Cancer Therapy (FACT) Fatigue (FACT-F) subscale. A three-point difference in FACT-F is clinically important. 3 The fatigue symptom scale from the EORTC QLQ-C30 was also studied. The QLQ-C30 features five functional scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting), and a global health measure. 4 Part way through the study, a single-item global measure of fatigue from the Edmonton Symptom Assessment Scale (ESAS) was added.
Mood was assessed with the 15-item Geriatric Depression Scale (GDS). 5 Functional status was measured using the Barthel instrument for basic activities of daily living (ADL) 6 and the Lawton-Brody scale for instrumental ADL (IADL). 7 To examine prevalence of fatigue at each time point, we examined the proportion of patients who reported at least mild fatigue (a score greater than 0 on the fatigue subscale of the QLQ-C30). Fatigue severity was evaluated with the ESAS fatigue question. To examine correlations between fatigue, QOL and functional status, Pearson's correlation coefficient was calculated at each time point between FACT-F scores and global health, the five QOL domains of the QLQ-C30, and measures of ADL/IADL. We used linear regression to examine correlations between predictor variables and fatigue. To examine change in Table 1 Baseline characteristics of patients (n ¼ 65) Letters to the Editor fatigue over time, we examined mean fatigue scores over time after grouping patients by treatment group (IC and non-IC) and remission status (complete remission (CR) or no CR). For all statistical comparisons, a P-value of 0.05 was considered significant. Given the exploratory nature of our analyses, and the relatedness of variables, no strict correction was made for multiple comparisons; however, we do report the levels of significance at various levels (.05, .01, .001) for the benefit of the reader. Analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC, USA).
A total of 65 patients (mean age 72.1 years, 71% male) were enrolled between June 2003 and January 2006. Baseline data are summarized in Table 1 . Global health was moderately impaired at baseline. Of six symptoms scores assessed by the QLQ-C30, fatigue was the highest scoring (i.e., most severe) symptom (Table 1) .
A total of 48 of 65 patients (74%) received IC. Compared with the non-IC group, patients who received IC were younger (70.2 versus 77.1 years, Po0.001) and had better Eastern Cooperative Oncology Group scores (0.93 versus 1.44, P ¼ 0.04) but did not differ in terms of gender, cytogenetic risk group, or Karnofsky performance status (all P40.05). At baseline, IC patients had better FACT-F scores (34 versus 26, P ¼ 0.03) and physical function scores (77 versus 55, Po0.001) but were otherwise similar to non-IC patients in QOL domains. At 6 months, 68% of patients were alive. There was significant patient attrition over time owing to death, disease progression and other factors ( Table 2) .
At baseline, 98% of patients reported some degree of fatigue. Corresponding figures at 1 month, 4 months and 6 months were 92, 97 and 93%, respectively. At baseline, fatigue severity was categorized as none-mild by eight patients (38%), moderate by 7 (33%) and severe by 6 (29%).
Fatigue scores were not correlated with age, gender, cytogenetic risk group or bone marrow blast percentage at baseline, or with hemoglobin level at any time point (Table 3) . Significant correlations were found between fatigue scores and both white blood cell (WBC) count and LDH level at each time point (Table 3 ). In linear regressions of change in fatigue scores from baseline to 1 month, there was no relationship with change in hemoglobin, whether or not we adjusted for baseline fatigue score, hemoglobin or age. Findings were similar using 4-month and 6-month time points.
Fatigue scores demonstrated moderate to strong correlations with global health and all five QOL domains at each time point (Table 3 ). The strongest correlations were with global health and physical function. Weak to moderate correlations were noted with both ADL and IADL at most time points (Table 3 ). Moderate to strong correlations were also found between fatigue scores and depression scores at all time points (Table 3) .
Fatigue appeared to improve slightly over time in both the IC and non-IC groups (Figure 1 ). However, patients who had died or withdrawn from the study had worse fatigue scores than those of remaining subjects (data not shown). Among IC patients, achievement of remission did not appear to be associated with significant improvements in fatigue scores ( Figure 2 ).
Our study is the largest to date and the first study to examine fatigue in detail among older adults with AML. We found that fatigue was almost universal at each time point and remained Table 2 Response rates and reasons for non-completion of study by time points Letters to the Editor problematic for most patients over time. This is consistent with data from other studies in AML 2 and other malignancies. 1 We also found that fatigue was inversely correlated with global health, major domains of QOL, and self-reported ADLs. These findings are new, and highlight the importance and wideranging impact of fatigue in older patients with AML. Although our study design does not allow us to make causal inferences about fatigue in relation to these other variables, the most plausible explanation is that fatigue significantly limits a patient's perception of their ability to function in the various domains that were considered. As we did not objectively measure physical fitness or exercise tolerance, it remains unclear if perceived impairment correlates with observed performance. This hypothesis requires further study.
Our study also demonstrated correlations between fatigue scores and both WBC counts and LDH levels at multiple time points. One possible explanation is that WBC count and LDH level may reflect the burden of rapid cell turnover or breakdown, with resultant leakage of intracellular contents and alterations in cytokine levels. One preliminary study suggested a link between cytokines and fatigue among patients with AML. 8 This area warrants formal study. The strong and consistent correlations with depressive symptoms suggests this may represent another intervention target.
Although fatigue scores do not improve much over time, longer follow-up with careful attention to attrition is likely necessary to disentangle the fatigue-inducing effects of chemotherapy from possible fatigue reduction with better disease control.
Several limitations must be kept in mind when interpreting our data. First and foremost, despite being the largest study to date, our sample size is still modest, particularly at the 4 and 6-month time points, owing to attrition, limiting our ability to examine changes over time. Additionally, as all of our patients were enrolled from a single institution and were fluent in English, our findings may not be generalizable to other settings and patient groups.
In summary, fatigue is an almost universal symptom among older adults with AML at the time of diagnosis, and it persists up to 6 months after diagnosis. Fatigue is associated with reductions in all domains of QOL, and appears to adversely affect basic and instrumental ADL function as well. Future studies need to focus on exploring relationships between fatigue and depression, cytokines and other factors in order to identify potential intervention targets. 
Figure 2
Mean FACT-F fatigue scores by treatment group and remission status. In the above figure, each bar depicts the mean fatigue score for all responding patients at that time point. The number of responding patients is shown below the x-axis. Patients are grouped by those who underwent intensive treatment and either achieved complete remission (IC with CR) or did not (IC without CR), and by those who underwent non-intensive treatment (no IC).
